You are here: Industry Insights > Bio-Thera Solutions

News List

China NMPA Approves Bio-Thera Solutions’ QLETLI®, A Biosimilar To Humira® (Adalimumab) bio-thera
November 08, 2019
Approval Based on Totality of Evidence Demonstrating That QLETLI® Is Biosimilar to Humira® First Approved Biosimilar From Bio-Thera's Biosimilar Portfolio.
Bio-Thera Solutions Announces Initiation of Phase III Clinical Trial for BAT1806, a Proposed Biosimilar of Actemra firstwordpharma
January 23, 2019
Bio-Thera Solutions, a clinical-stage pharmaceutical company, today announced that dosing has begun in a Phase III clinical study for its tocilizumab biosimilar, BAT1806. Bio-Thera's Phase III clinical trial will compare the safety and efficacy of BAT1806
Bio-Thera Solutions Announces Initiation of Phase III Clinical Trial for BAT1806, a Proposed Biosimilar of Actemra firstwordpharma
January 23, 2019
Bio-Thera Solutions, a clinical-stage pharmaceutical company, today announced that dosing has begun in a Phase III clinical study for its tocilizumab biosimilar, BAT1806. Bio-Thera's Phase III clinical trial will compare the safety and efficacy of BAT1806
Bio-Thera Solutions Ltd Partners with Cipla Ltd to Market Key Cancer Biosimilar firstwordpharma
January 15, 2019
BAT-1706 is a mAb biosimilar to Genentech's Avastin® which is currently approved for six indications including metastatic colorectal cancer, recurrent glioblastoma and non-squamous non-small cell lung cancer.
Bio-Thera Solutions Files IND for Phase 1 Clinical Trial with BAT8003 americanpharmaceuticalreview
December 29, 2018
Bio-Thera Solutions announced the company has filed an Investigational New Drug Application (IND) with the China National Medical Products Administration (NMPA) for the company's anti-Trop2 Antibody-Drug Conjugate (ADC)....